Puma Biotechnology | PBYI - Операционные расходы

Биржевая цена
7.78
Изменение за день
-0.02 -0.26%
Ежемесячно
29.67%
Ежегодный
175.89%
Q2 прогноз
7.57




Операционные расходы Изменить Дата
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amgen USD 5.9B 773M 2025-12
Biogen USD 1.88B 81.4M 2025-09
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Exelixis USD 362.75M 21.35M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Incyte USD 1.12B 3.53B 2025-12
MacroGenics USD 53.32M 13.68M 2025-12
Moderna USD 1.54B 259M 2025-12
Novartis USD 9.8B 61M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
PTC Therapeutics USD 246.3M 38.78M 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Takeda JPY 1.02T 400.98B 2025-12
TG Therapeutics USD 142.08M 9.74M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vanda Pharmaceuticals USD 466M 20.33M 2025-09
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12